➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Baxter
Harvard Business School
AstraZeneca
Colorcon

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OMBITASVIR; PARITAPREVIR; RITONAVIR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Ombitasvir; Paritaprevir; Ritonavir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01458535 A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Completed AbbVie (prior sponsor, Abbott) Phase 2 2011-09-01 The purpose of this study was to evaluate the efficacy, safety and pharmacokinetics of ABT-450/r when given together with ABT-267 and with and without RBV in treatment-naïve participants with genotype 1, 2 or 3 chronic HCV infection.
NCT01672983 A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection Completed AbbVie (prior sponsor, Abbott) Phase 2 2012-07-01 This study evaluated the safety, tolerability, antiviral activity, and pharmacokinetics of ABT-450 (also known as paritaprevir) with ritonavir (ABT-450/r) and ABT-267 (also known as ombitasvir) in adult Japanese patients with chronic hepatitis C virus genotype 1b (HCV GT1b) or genotype 2 (HCV GT2) infection who were previous treated with pegylated interferon/ribavirin (pegIFN/RBV).
NCT01674725 A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C Completed AbbVie (prior sponsor, Abbott) Phase 3 2012-08-01 The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin (RBV) in patients with chronic hepatitis C virus genotype 1b (HCV GT1b) infection without cirrhosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ombitasvir; Paritaprevir; Ritonavir

Condition Name

Condition Name for Ombitasvir; Paritaprevir; Ritonavir
Intervention Trials
Chronic Hepatitis C Infection 11
Chronic Hepatitis C 8
Hepatitis C Virus 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ombitasvir; Paritaprevir; Ritonavir
Intervention Trials
Hepatitis C 33
Hepatitis 32
Hepatitis A 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ombitasvir; Paritaprevir; Ritonavir

Trials by Country

Trials by Country for Ombitasvir; Paritaprevir; Ritonavir
Location Trials
United States 86
Australia 7
Egypt 5
United Kingdom 5
Spain 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ombitasvir; Paritaprevir; Ritonavir
Location Trials
Texas 7
New York 7
Florida 7
North Carolina 7
California 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ombitasvir; Paritaprevir; Ritonavir

Clinical Trial Phase

Clinical Trial Phase for Ombitasvir; Paritaprevir; Ritonavir
Clinical Trial Phase Trials
Phase 4 6
Phase 3 19
Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ombitasvir; Paritaprevir; Ritonavir
Clinical Trial Phase Trials
Completed 19
Recruiting 9
Not yet recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ombitasvir; Paritaprevir; Ritonavir

Sponsor Name

Sponsor Name for Ombitasvir; Paritaprevir; Ritonavir
Sponsor Trials
AbbVie 21
AbbVie (prior sponsor, Abbott) 6
Assiut University 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ombitasvir; Paritaprevir; Ritonavir
Sponsor Trials
Industry 27
Other 17
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Baxter
McKinsey
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.